注射用埃索美拉唑钠联合生长抑素治疗非静脉曲张性上消化道出血的应用
|
摘要
目的对埃索美拉唑钠针剂联合生长抑素治疗非静脉曲张性上消化道出血的有效性评价进行分析。方法选取2015年3月-2018年3月期间收治的132例非静脉曲张上消化道出血患者,随机分为对照组(n=66)与观察组(n=66),对照组采用埃索美拉唑钠针剂治疗,观察组应用埃索美拉唑钠针剂联合生长抑素治疗,对两组患者止血时间、输血量,治疗效果、住院时间、不良反应进行比较。结果观察组止血时间(23.32±4.87)小时,输血量(2.49±0.47)单位,明显低于对照组观察止血时间(27.89±5.22)小时,输血量(3.21±0.66)单位,差异有统计学意义(P<0.05)。观察组治疗效果有效率98.48%,高于对照组的89.39%;观察组住院时间(9.65±0.46)天,低于对照组的(11.41±0.27)天;观察组不良反应发生率7.58%,低于对照组22.73%,差异均有统计学意义(P<0.05)。结论埃索美拉唑钠针剂联合生长抑素治疗上消化道出血具有较好的临床疗效,止血成功率较高,且具有较好临床应用安全性,为临床治疗非静脉曲张性上消化道出血提供依据。
Objective To evaluate the efficacy of esomeprazole sodium injection combined with somatostatin in the treatment of non-varicose upper gastrointestinal hemorrhage. Methods 132 patients with non-varicose upper gastrointestinal bleeding from March 2015 to March 2018 were randomly divided into two groups: control group(n=66)and observation group(n=66). The control group was treated with esomeprazole sodium injection. The observation group was treated with esomeprazole sodium injection combined with somatostatin. The hemostasis time, blood transfusion volume, therapeutic effect, hospitalization time and adverse reaction were compared between the two groups. Results The hemostasis time was 23.32 in the observation group. The blood transfusion volume(2.49±0.47)unit was significantly lower than that in the control group(27.89±5.22)hours, and the blood transfusion volume was(3.21±0.66)units in the control group(P<0.05). The effective rate of treatment in the observation group was 98.48% higher than that in the control group 89.39%,and the hospitalization time in the observation group was(9.65± 0.46)days lower than that in the control group(11.41±0.27)days. The incidence of adverse reactions in the observation group was 7.58% lower than that in the control group(22.73 g)(P<0.05). Conclusions Esomeprazole sodium injection combined with somatostatin in the treatment of upper gastrointestinal bleeding had a better clinical efficacy, a high success rate of hemostasis and a better clinical safety, which provided a basis for clinical treatment of non-varicose upper gastrointestinal hemorrhage.
Objective To evaluate the efficacy of esomeprazole sodium injection combined with somatostatin in the treatment of non-varicose upper gastrointestinal hemorrhage. Methods 132 patients with non-varicose upper gastrointestinal bleeding from March 2015 to March 2018 were randomly divided into two groups: control group(n=66)and observation group(n=66). The control group was treated with esomeprazole sodium injection. The observation group was treated with esomeprazole sodium injection combined with somatostatin. The hemostasis time, blood transfusion volume, therapeutic effect, hospitalization time and adverse reaction were compared between the two groups. Results The hemostasis time was 23.32 in the observation group. The blood transfusion volume(2.49±0.47)unit was significantly lower than that in the control group(27.89±5.22)hours, and the blood transfusion volume was(3.21±0.66)units in the control group(P<0.05). The effective rate of treatment in the observation group was 98.48% higher than that in the control group 89.39%,and the hospitalization time in the observation group was(9.65± 0.46)days lower than that in the control group(11.41±0.27)days. The incidence of adverse reactions in the observation group was 7.58% lower than that in the control group(22.73 g)(P<0.05). Conclusions Esomeprazole sodium injection combined with somatostatin in the treatment of upper gastrointestinal bleeding had a better clinical efficacy, a high success rate of hemostasis and a better clinical safety, which provided a basis for clinical treatment of non-varicose upper gastrointestinal hemorrhage.
引文
[1]高成广,谢峰,冯亚东.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的效果观察[J].临床肝胆病杂志,2016,32(2):284-287.
[2]庄建荣,郑培英,甘惠贞.奥曲肽与生长抑素治疗肝硬化上消化道出血疗效和安全性比较的Meta分析[J].中国药师,2017,20(12):2204-2208.
[3]仲敏,陆晓晔,朱长清.奥曲肽与生长抑素治疗肝硬化合并上消化道出血疗效对比研究[J].陕西医学杂志,2016,45(10):1409-1411.
[4]王琼,王景,邓菁,等.生长抑素和特利加压素单用或联用治疗肝硬化上消化道出血成本-效果分析[J].中国现代医生,2015,53(28):49-52.
[5]Tseng T C,Liu C J,Yang H C,et al.Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers.[J].Gut,2015,64(2):292-302.
[6]徐振瑞,夏炳涛.生长抑素联合奥美拉唑治疗肝硬化上消化道出血的临床观察[J].疾病监测与控制,2015,9(5):347-349.
[7]铁艳峰.奥曲肽、生长抑素治疗肝硬化上消化道出血疗效分析[J].医学理论与实践,2016,29(6):752-753.
[8]高成广,谢峰,冯亚东.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的效果观察[J].临床肝胆病杂志,2016,32(2):284-287.
[9]虞萍,周美芳,刘虹,等.生长抑素联合垂体后叶素配合护理干预治疗肝硬化上消化道出血45例[J].中国药业,2015,24(19):100-102.
[10]徐振瑞,夏炳涛.生长抑素联合奥美拉唑治疗肝硬化上消化道出血的临床观察[J].疾病监测与控制,2015,9(5):347-349.
[11]周德江,曾维政.生长抑素用于治疗肝硬化上消化道出血的临床价值分析[J].现代消化及介入诊疗,2015,20(2):153-154.
[12]麦国.奥曲肽与生长抑素治疗肝硬化上消化道出血的有效性与安全性比较[J].中国医学工程,2014,22(10):116,120.
[13]于仕杰,刘军.生长抑素治疗肝硬化上消化道出血180例临床观察[J].实用医院临床杂志,2014,11(3):102-103.
[14]赵寒冰,张永宏,韦波.幽门螺杆菌感染与肝硬化患者上消化道出血的相关性研究[J].中华医院感染学杂志,2013,23(17):4143-4145.
[15]彭微微,赵守松.进口与国产生长抑素治疗肝硬化并发上消化道出血效果观察[J].实用肝脏病杂志,2013,16(2):113-115.
[16]犹春均.生长抑素、垂体后叶素治疗肝硬化上消化道出血临床效果分析[J].中国实用医药,2018,13(10):123-124.
[17]陈玉.肝硬化上消化道出血治疗中生长抑素使用剂量的影响作用[J].中外医学研究,2018,16(2):141-143.
[18]庄建荣,郑培英,甘惠贞.奥曲肽与生长抑素治疗肝硬化上消化道出血疗效和安全性比较的Meta分析[J].中国药师,2017,20(12):2204-2208.
[19]黄少妙.生长抑素与奥曲肽治疗肝硬化上消化道出血的临床疗效分析[J].现代诊断与治疗,2017,28(2):252-254.
[20]缪向来,潘晨,艾常华,等.奥曲肽与生长抑素对肝硬化并上消化道出血的疗效及对血流动力学的影响[J].现代消化及介入诊疗,2016,21(6):878-880.
[21]李云丽,柏保利,庄林.生长抑素治疗肝硬化上消化道出血68例临床观察[J].中国社区医师,2016,32(33):42,44.
[22]王志霖.生长抑素联合垂体后叶素治疗对肝硬化上消化道出血患者的疗效评价[J].青海医药杂志,2016,46(11):20-22.
[2]庄建荣,郑培英,甘惠贞.奥曲肽与生长抑素治疗肝硬化上消化道出血疗效和安全性比较的Meta分析[J].中国药师,2017,20(12):2204-2208.
[3]仲敏,陆晓晔,朱长清.奥曲肽与生长抑素治疗肝硬化合并上消化道出血疗效对比研究[J].陕西医学杂志,2016,45(10):1409-1411.
[4]王琼,王景,邓菁,等.生长抑素和特利加压素单用或联用治疗肝硬化上消化道出血成本-效果分析[J].中国现代医生,2015,53(28):49-52.
[5]Tseng T C,Liu C J,Yang H C,et al.Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers.[J].Gut,2015,64(2):292-302.
[6]徐振瑞,夏炳涛.生长抑素联合奥美拉唑治疗肝硬化上消化道出血的临床观察[J].疾病监测与控制,2015,9(5):347-349.
[7]铁艳峰.奥曲肽、生长抑素治疗肝硬化上消化道出血疗效分析[J].医学理论与实践,2016,29(6):752-753.
[8]高成广,谢峰,冯亚东.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的效果观察[J].临床肝胆病杂志,2016,32(2):284-287.
[9]虞萍,周美芳,刘虹,等.生长抑素联合垂体后叶素配合护理干预治疗肝硬化上消化道出血45例[J].中国药业,2015,24(19):100-102.
[10]徐振瑞,夏炳涛.生长抑素联合奥美拉唑治疗肝硬化上消化道出血的临床观察[J].疾病监测与控制,2015,9(5):347-349.
[11]周德江,曾维政.生长抑素用于治疗肝硬化上消化道出血的临床价值分析[J].现代消化及介入诊疗,2015,20(2):153-154.
[12]麦国.奥曲肽与生长抑素治疗肝硬化上消化道出血的有效性与安全性比较[J].中国医学工程,2014,22(10):116,120.
[13]于仕杰,刘军.生长抑素治疗肝硬化上消化道出血180例临床观察[J].实用医院临床杂志,2014,11(3):102-103.
[14]赵寒冰,张永宏,韦波.幽门螺杆菌感染与肝硬化患者上消化道出血的相关性研究[J].中华医院感染学杂志,2013,23(17):4143-4145.
[15]彭微微,赵守松.进口与国产生长抑素治疗肝硬化并发上消化道出血效果观察[J].实用肝脏病杂志,2013,16(2):113-115.
[16]犹春均.生长抑素、垂体后叶素治疗肝硬化上消化道出血临床效果分析[J].中国实用医药,2018,13(10):123-124.
[17]陈玉.肝硬化上消化道出血治疗中生长抑素使用剂量的影响作用[J].中外医学研究,2018,16(2):141-143.
[18]庄建荣,郑培英,甘惠贞.奥曲肽与生长抑素治疗肝硬化上消化道出血疗效和安全性比较的Meta分析[J].中国药师,2017,20(12):2204-2208.
[19]黄少妙.生长抑素与奥曲肽治疗肝硬化上消化道出血的临床疗效分析[J].现代诊断与治疗,2017,28(2):252-254.
[20]缪向来,潘晨,艾常华,等.奥曲肽与生长抑素对肝硬化并上消化道出血的疗效及对血流动力学的影响[J].现代消化及介入诊疗,2016,21(6):878-880.
[21]李云丽,柏保利,庄林.生长抑素治疗肝硬化上消化道出血68例临床观察[J].中国社区医师,2016,32(33):42,44.
[22]王志霖.生长抑素联合垂体后叶素治疗对肝硬化上消化道出血患者的疗效评价[J].青海医药杂志,2016,46(11):20-22.